The pharmaceutical industry may be fighting a first-in-the-nation law in Nevada to demand pricing transparency on diabetes drugs, but Colorado legislator Dylan Roberts is not deterred.

Last week, he introduced a bill to similarly demand that drug makers report pricing histories, explain price hikes, disclose costs, and reveal the rebates paid to pharmacy benefit managers. And as in Nevada, he hopes the legislation will slow the cost of caring for diabetes. In Colorado, about $720 million, or 19 percent, of all diabetes care is spent on prescription drugs to control the disease, according to the bill.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy